Search clinical trials for: PF-06865571 Slow release MR tablets

Total 25 results

Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Alexion Pharmaceuticals, Inc.

Completed

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Lung Biotechnology PBC

Completed

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Healthy

United States
Janssen Korea, Ltd., Korea

Completed

Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission (PERFECT)

Schizophrenia

Korea, Republic of
University of California, San Diego

Active, not recruiting

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS)

Hiv | Hormone Therapy

United States
Gilead Sciences

Not yet recruiting

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection
Guangzhou Women and Children's Medical Center

Completed

Intranasal Dexmedetomidine VS Oral Chloral Hydrate for Rescue Sedation During Magnetic Resonance Imaging

Failed Moderate Sedation During Procedure | Administration Related Reaction | Chloral Hydrate Adverse Reaction

China
Wayne State University

Completed

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)

Heroin Dependence | Opioid Use Disorder

United States
Assembly Biosciences

Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand
Children's Oncology Group
National Cancer Institute (NCI); SpringWorks Therapeutics, Inc.

Active, not recruiting

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Desmoid Fibromatosis | Recurrent Desmoid Fibromatosis | Unresectable Desmoid Fibromatosis

United States, Canada, Puerto Rico, Australia, New Zealand
Yang I. Pachankis

Completed

Medicine-induced Cardiac Hemodialysis on COVID-19

Renal Dialysis | Vaccines | Infection Viral | Severe Acute Respiratory Syndrome-related Coronavirus | Myocarditis Allergic

China

3

Subscribe